Earnings

Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine

Sep 30, 2026 · 08:40 AM ET· updated 1h ago

Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute

Why It Matters

Ernexa's experimental medicine ERNA-101 passed safety tests with no harmful effects. When a new medicine passes early safety checks, it means the company can move forward to test it in people.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ERNA3.33

+0.17 (+5.38%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.